In a report published Wednesday, Sterne Agee analyst Greg T. Bolan resumed coverage on MedAssets MDAS with a Buy rating and $24.00 price target.
In the report, Sterne Agee noted, “We see profitability improving substantially as the company's GPO business continues to dominate market share and adoption of RCM IT applications improves following hospitals' race to achieve initial requirements under the CMS EHR incentive program. Re-initiate coverage with Buy rating and $24 price target.”
MedAssets closed on Tuesday at $17.31.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in